Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

被引：0

作者：

Zhang, Fan

Hu, Yi

Han, Xiao

Hu, ZhiSong

机构：

[1] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China

[2] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9151

引用

页数：1